Business
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on
About this update from Pliant Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced presentations made at the European Respiratory Society (ERS) International Congress 2023 taking place from September 9, 2023 to September 13, 2023. “We are pleased to be sharing non-clinical and clinical data at this important congress, including, for the first time at a scientific session, the final results from our INTEGRIS-IPF Phase 2a trial. Data from this trial support the late-stage development of bexotegrast as part of the BEACON-IPF trial and highlight our commitment to developing potential treatments for fibrotic diseases,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF Study (NCT04396756) Findings from the 24-week analysis of our recently completed INTEGRIS-IPF Phase 2a trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF) were presented in late-breaking oral and e-poster forms. Results showed that bexotegrast at 320 mg was well tolerated for up to 40 weeks of treatment with no discontinuations due to treatment-emergent adverse events occurring from Week 12 to Week 40. Additionally, over 24 weeks, a durable treatment effect on forced vital capacity (FVC) was observed in a population predominantly using IPF background therapies (nintedanib or pirfenidone). Quantitative lung fibrosis (QLF) imaging continued to demonstrate the antifibrotic mechanism of bexotegrast: at Week 24, the proportion of bexotegrast 320 mg-treated participants who experienced a stabilization or improvement of fibrosis was twice as high as those in the placebo group. Dual αVβ6/αVβ1 integrin inhibitor bexotegrast reduces fibrogenesis in pathological cell populations present in the fibrotic human lung Results from a single nuclei RNASeq analysis of bexotegrast-treated precision-cut lung slices prepared from fibrotic human tissue were presented in oral and poster forms. Results showed that bexotegrast treatment reduced the expression of pro-fibrogenic genes and pathways in pro-fibrotic (CTHRC1+) fibroblasts, as well as in aberrant basaloid cells known to express integrin αVβ6. Cir...